Clinidipine is the new type of CaA accompanied with L type and N type Calcium - channel blocking function. It is jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatement in 1995. CaA is another kind of rapidly developed angiomyocardiac followed b-blocking agent in the recent 10 years and widely used for high blood pressure, angina cordis, syndrome of myocardial ischemia, cerebrovascular disease and peripheral arterial disease clinically with the reputation of one of the five great progress in heart disease treatment. Compared with other CaA, clinidipine can act on the N type calcium-channel that existing sympathetic nerve end besides acting on L type calcium-channel that similar to most of the CaAs. With higher curative effect on lower the blood pressure and anti-atherosclerosis effect, the average effective rate of this product can be above 90% while the rate of side effect is below 10%. This product is the high blood pressure medicine with long effect, take it once per day and one grain per time for blood pressure control.

　　Among worldwide cardiovascular drug market, the sales amount has reached above USD30 billion, which occupies 18.5% of the world medicine sale and stands at the first place. Cardiovascular disease seriously threats people’s health, its attack rate and death rate are placed in the first position among all the diseases in many countries all over the world as the “No. one hangman” that kills human beings. According to statistics, the attack rate of cardiovascular disease in our country is increasing year by year, take high blood pressure as an example, the countrywide sampling census in year 1959, 1979 and 1991 indicated that, the attack rate of high blood pressure increases nearly 50% every 10 years. The census number of patients taken in 1991 was more than 90 million. Last year, after our country lowered the diagnosis standard of high blood pressure to diastolic pressure of more than 90mm Hg and systolic pressure of more than 140mm Hg, the number of high blood pressure patients increased by 40 million, so the total number increased to 130-150 million, which predicts that there is wide marketing space for cardiovascular drugs. In accordance with the statistics by related department, the domestic sales amount of cardiovascular drugs in year 2001 was about RMB10 billion, including 75% liquid agent, and the sales amount increases at an average rate of 12% annually. Therefore, research institutes and pharmaceutical companies keep on paying great attention on developing cardiovascular drugs. Clinidipine tablet, capsule and soft capsule are newly developed in our country but not on the market. Compared with tablets and capsule, soft capsule has higher science and technology content as well as stronger competitive power. At present, cardiovascular drugs appeared on domestic medicine market are amlodipine, nifedipine and nisoldipine etc. Clinidipine possesses advantages on curative effect, side effect and price. It is possible to gain certain market share predicted by static market. The price of clinidipine is fixed at RMB1.00 per grain. The sales amount can reach RMB80 million counted by annual sales volume of 100 million grains. The profit can be RMB16 million counted by the profit rate of 20%. The profit will be considerable if operate marketing properly.